PMCB Stock - PharmaCyte Biotech, Inc.
Unlock GoAI Insights for PMCB
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| Operating Income | $-4,377,862 | $-6,520,008 | $-6,455,000 | $-4,392,000 | $-3,623,000 |
| Net Income | $30.66M | $333,763 | $-4,316,000 | $-4,239,161 | $-3,554,000 |
| Net Margin | N/A | N/A | N/A | N/A | N/A |
| EPS | $3.19 | $-1.80 | $-0.22 | $-0.27 | $-2.46 |
PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer, as well as diabetes. The company is developing therapies for pancreatic and other solid cancerous tumors; a therapy for Type 1 diabetes and insulin-dependent Type 2 diabetes, which include encapsulated genetically modified insulin-producing cells; and therapies for cancer based on the constituents of the cannabis plant. It has a research agreement with the University of Technology, Sydney to create a version of melligen cells to treat diabetes; and the University of Northern Colorado to develop methods for the identification, separation, and quantification of constituents of cannabis. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.
Visit WebsiteEarnings History & Surprises
PMCBEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 16, 2026 | — | — | — | — |
Q4 2025 | Dec 18, 2025 | — | $-0.32 | — | — |
Q3 2025 | Sep 15, 2025 | — | $-0.09 | — | — |
Q3 2025 | Aug 11, 2025 | — | $1.73 | — | — |
Q1 2025 | Mar 17, 2025 | — | $-0.10 | — | — |
Q4 2024 | Dec 13, 2024 | — | $-0.29 | — | — |
Q3 2024 | Sep 16, 2024 | — | $0.14 | — | — |
Q3 2024 | Aug 13, 2024 | — | $-0.85 | — | — |
Q1 2024 | Mar 18, 2024 | — | $-0.65 | — | — |
Q4 2023 | Dec 15, 2023 | — | $-0.64 | — | — |
Q3 2023 | Sep 18, 2023 | — | $-0.28 | — | — |
Q3 2023 | Jul 31, 2023 | $-0.09 | $-0.01 | +88.9% | ✓ BEAT |
Q1 2023 | Mar 16, 2023 | $-0.08 | $-0.04 | +50.0% | ✓ BEAT |
Q4 2022 | Dec 14, 2022 | $-0.08 | $-0.09 | -12.5% | ✗ MISS |
Q3 2022 | Sep 14, 2022 | $-0.07 | $-0.07 | 0.0% | = MET |
Q3 2022 | Jul 28, 2022 | $-0.03 | $-0.06 | -75.0% | ✗ MISS |
Q1 2022 | Mar 15, 2022 | $-0.05 | $-0.04 | +20.0% | ✓ BEAT |
Q4 2021 | Dec 14, 2021 | $-0.07 | $-0.06 | +14.3% | ✓ BEAT |
Q3 2021 | Sep 14, 2021 | — | $-0.64 | — | — |
Q3 2021 | Aug 10, 2021 | — | $-0.62 | — | — |
Latest News
PharmaCyte Biotech Receives Noncompliance Notice From Nasdaq; Has Until June 2026 To Regain Compliance
📉 NegativePharmaCyte Biotech shares are trading higher after the company announced monetization of its stake in Femasys.
📈 PositivePharmaCyte Biotech Monetizes Femasys Stake; Cash And Securities Expected At ~$20M After Monetization, Up From $13.3M
📈 PositivePharmaCyte Biotech Q1 EPS $(1.23) Down From $1.90 YoY
📉 NegativePharmaCyte Biotech Invests Additional $3M In TNF Pharmaceuticals To Support LightSolver Partnership
📈 PositiveFrequently Asked Questions about PMCB
What is PMCB's current stock price?
What is the analyst price target for PMCB?
What sector is PharmaCyte Biotech, Inc. in?
What is PMCB's market cap?
Does PMCB pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to PMCB for comparison